Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03032484 · ClinicalTrials.gov registry record · Phase 2
TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03032484: Completed Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT03032484 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03032484, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
Primary Outcome
Survival of participants at 6 months after the start of treatment without their condition becoming any worse. Brain magnetic resonance imaging (MRI) was performed after every even cycle (e.g., C2, C4) during treatment, with tumor response assessed by the investigator for complete response (CR), partial response (PR) and PD according to the Response Assessment in Neuro-oncology (RANO) criteria.
Interventions
- DRUG Bevacizumab
- DRUG TVB-2640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2021-04-05 |
| Phase | Phase 2 |
What the finished NCT03032484 record still lists
NCT03032484 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT03032484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03032484 about?
NCT03032484 is a clinical study titled "TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma". Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
What is the current status of trial NCT03032484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2017-05-18. Estimated completion is 2021-04-05.
What interventions are being tested in trial NCT03032484?
The interventions under investigation include: Bevacizumab (DRUG), TVB-2640 (DRUG).
Who is sponsoring clinical trial NCT03032484?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03032484's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI